What is the STELLAR trial?
Better treatment options are needed for patients with recurrent anaplastic astrocytoma (or rAA).
The purpose of the STELLAR trial is to study eflornithine oral solution as a possible new treatment for patients with rAA, and the trial is now open for enrollment.
In the STELLAR trial, patients with rAA will receive treatment with either eflornithine in combination with lomustine, or lomustine by itself. Patients are randomly assigned to one of the two treatment groups. Treatment lasts up to 12 or 24 months, depending on the treatment group. Treatment is followed by an observation period for up to 24 months.
The STELLAR trial is registered with the United States Government clinical trials registry and with the European Union Clinical Trials Registry.
For more information about the STELLAR trial on the United States Government clinical trials registry, click here
To find information about the STELLAR trial in the European Union Clinical Trials Register, click here
Anaplastic Astrocytoma (or AA) is a rare form of brain cancer. AA develops from astrocytes, a type of cell that normally wraps and protects nerves in the brain and spinal cord. The specific cause of AA is not known. Most AAs grow slowly over time, but some grow quickly. Some AAs transform to become a more aggressive type of tumor called glioblastoma.
AA is most common in adults aged 30 to 50 years, although it can affect all ages. A detailed list of symptoms, complete physical exam, and imaging tests, such as an MRI or a CT scan of the brain, are part of the medical evaluation. The diagnosis of AA may be confirmed by collecting tumor tissue during surgery for inspection under a microscope and for specialized genetic tests.
Surgery, radiation therapy, and chemotherapy can be used alone or together to treat AA. Treatment usually begins with surgery to reduce the size of the tumor. Surgery is usually followed by radiation therapy and chemotherapy with temozolomide (the generic drug name for Temodar®). The type and sequence of therapies may be different for each patient, depending on each unique situation.
When the tumor starts to grow after treatment, AA is called recurrent anaplastic astrocytoma (or rAA). Currently, there are very few therapies for patients with rAA or AA that has progressed (grown larger or changed in appearance).
Source: NORD National Organization of Rare Disorders website